
    
      The study has two groups: Group HRV and Group Placebo. Two oral doses administered to healthy
      infants who are 6-12 weeks of age at the time of Dose 1, according to a 0, 1 to 2-month
      schedule. Routine EPI vaccinations are given at the discretion of the investigator and
      according to local National Plans of Immunisation schedule in each participating country.
    
  